TOPLINE:

A standard-dose recombinant growth hormone therapy administered for 2 years demonstrated positive effects on both growth and nutritional status in prepubertal children with Silver-Russell syndrome , a condition characterized by severe growth retardation and feeding difficulties. Initiating treatment before the age of 4 years optimized height gains in these patients.

METHODOLOGY:

About 90% of children with Silver-Russell syndrome have severe feeding difficulties, primarily before the age of 6 years, and nearly 70% are malnourished. Data on the effects of recombinant growth hormone, especially during the initial years of therapy, are limited.

To address this gap, researchers conducted a retrospective single-center analysis of 77 children (including 36 girls) with no sign of pu

See Full Page